Kiplinger

The 7 Best Biotech Stocks for Investors Who Hate Risk

Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the expiration of a crucial patent leading to massive stock plunges have circulated for years now, souring would-be buyers on the entire industry.

However, conclusions based on a handful of biotech stocks may have erroneously prevented investors from plugging into a perfectly reasonable risk-reward relationship. Said differently: Not all biotech stocks turn into disasters. The industry as a group is up nearly 70% for the past five years, proving many of these companies can reward patient shareholders who choose wisely. It's simply a matter of doing your homework and having a little common sense.

Here are seven biotech stocks that aren't nearly as risky as their typical peer. Thus, they may have a place in more risk-averse portfolios than most investors might presume.

Amgen

Market value: $132.3 billion

The biggest biopharmaceutical companies don't always win all the spoils. A small outfit with a novel idea and a little know-how certainly is capable of coming

You're reading a preview, sign up to read more.

More from Kiplinger

Kiplinger17 min read
The 19 Best Stocks To Buy For The Rest Of 2019
The past year has been exciting, if not a little stomach-churning. A raucous 25% rally to start the year unwound a miserable last few months of 2018, but that big advance has been chopped by one-third just since the beginning of May. Thus, when picki
Kiplinger4 min read
Investing With A Conscience: The Rise Of ESG And What Really Matters To Investors
Socially responsible investing has really blossomed in the past few years. What used to be viewed as a niche investment philosophy is now firmly planted in the mainstream, with everyday consumers using their dollars to support companies that align wi
Kiplinger4 min read
Don't Be Fooled: 5 Steps to Help Avoid Financial Scams
Scam artists are more prevalent now than ever. In fact, Americans reported losing $1.5 billion to fraud in 2018, up 38% from 2017, according to the Federal Trade Commission. And in today's information age, when much of our financial life is managed t